品牌不一致的组织扩张器与植入物在分期乳房再造中的安全性
回顾性分析2018至2023年九位外科医生在四级癌症中心完成的496例组织扩张器置换为植入物的手术,其中330例(67%)品牌一致、166例(33%)品牌不一致。倾向评分匹配后,品牌不一致组总体并发症(5.9% vs 6.7%,p=0.80)和修整手术率(19% vs 16%,p=0.42)与一致组无显著差异,提示品牌不一致配对安全。
要点
- 品牌不一致配对不增加总体并发症或修整风险。
- 匹配前不一致组乳房固定术、新植入物放置及包膜切开/缝合更常见。
- 患者与治疗特征而非品牌一致性是结局的主要决定因素。
核心结论
- 品牌不一致的组织扩张器与植入物配对在分期乳房再造中是安全的,调整基线因素后不增加并发症或修整风险。
研究设计与样本
- 回顾性队列研究,纳入2018至2023年九位外科医生在四级癌症中心连续完成的496例组织扩张器置换为植入物手术,按制造商一致与否分组,并使用倾向评分匹配平衡术前差异。
主要发现
- 496例置换中330例(67%)品牌一致,166例(33%)品牌不一致,不一致最常见于Mentor与Allergan设备之间。
- 未匹配分析中总体并发症发生率相似(5.2% vs 7.2%,p=0.35),感染、血清肿和移位率相当。
- 未匹配分析中修整手术发生率一致组14%、不一致组18%(p=0.23),但乳房固定术(0% vs 4.2%,p<0.001)、新植入物放置(2.7% vs 7.8%,p=0.009)和包膜切开/包膜缝合术(0.6% vs 3.0%,p=0.045)在品牌不一致组更常见。
- 倾向评分匹配后每组135例,总体并发症(5.9% vs 6.7%,p=0.80)和修整手术率(19% vs 16%,p=0.42)仍保持均衡。
临床怎么用
- 临床中因可获得性、患者或医生偏好或术中考虑而出现品牌不一致配对时,无需过度担忧其安全性。
- 决策应更关注患者与治疗特征,而非强制要求组织扩张器与植入物品牌一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Device manufacturers generally recommend using concordant tissue expanders (TE) and implants during staged implant-based breast reconstruction (IBBR). In practice, discordant pairings may occur due to availability, patient or surgeon preference, or intraoperative considerations, but the impact of such mismatches on outcomes remains unclear. METHODS: Consecutive TE-to-implant exchanges (2018-2023) across nine surgeons at a quaternary cancer center were retrospectively reviewed. Patients were categorized as concordant or discordant based on manufacturer match. Propensity score matching minimized preoperative differences. Outcomes included surgical complications, implant-related morbidity, and revision procedures. RESULTS: Among 496 exchanges, 330 (67%) were concordant and 166 (33%) discordant. Discordance was most frequent between Mentor and Allergan devices. Unmatched analyses showed similar overall complications (5.2% vs. 7.2%, p=0.35) and comparable rates of infection, seroma, and malposition. Revisions occurred in 14% of concordant and 18% of discordant cases (p=0.23), with mastopexy (0% vs. 4.2%, p<0.001), new implant placement (2.7% vs. 7.8%, p=0.009), and capsulotomy/capsulorrhaphy (0.6% vs. 3.0%, p=0.045) more frequent in discordant exchanges. After propensity score matching (n=135 per group), outcomes remained balanced, including overall complications (5.9% vs. 6.7%, p=0.80) and revision rates (19% vs. 16%, p=0.42). CONCLUSIONS: Discordant TE-implant pairings are safe and do not increase complications or revision risk after adjustment for baseline factors. These results suggest that patient and treatment characteristics, rather than manufacturer concordance, are the primary determinants of outcomes in staged IBBR.
引用
- Elmorsi R, Shay P, Babu A, et al. Safety of Brand Discordant Tissue Expanders and Implants in Staged Breast Reconstruction. Plast Reconstr Surg. 2026. PMID: 41874323. doi:10.1097/PRS.0000000000013066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。